Geron and University of Edinburgh collaborate on development of cell types derived from human embryonic stell cells
Geron Corporation and the University of Edinburgh have entered into a collaboration to conduct preclinical safety and efficacy studies with three cell types derived from human embryonic stem cells (hESCs). The cell types are hepatocytes for the treatment of liver failure and osteoblasts and chondrocytes for the treatment of musculoskeletal disorders, including osteoarthritis, bone fractures and osteoporosis. The studies, based at the University's Centre for regenerative medicine, will be under the direction of Professor John Iredale, Dr. Phil Newsome, Dr. Brendon Noble and Professor Hamish Simpson.
"The milestones and endpoints of these programs were collaboratively defined, with Geron contributing its expertise on the design and execution of IND-enabling (Investigational New Drug) studies," said Dr. Jane Lebkowski, Geron's senior vice president of regenerative medicine. "We are enthusiastic about conducting these studies at the University of Edinburgh because of the infrastructure in place at the New Royal Infirmary in Little France. Moreover, the lead investigators include experienced hESC researchers and practicing physicians whose expertise will be useful to progress these cell types to the clinic."
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
